Related Experiment Video
Updated: Aug 6, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
NIR-II-activated supramolecular LDH nanoarchitecture integrated with 3D-printed bioactive glass for hypoxia-resistant
Hong Cheng1, Tao Wang2, Hanji Huang3
1Guangxi Engineering Center in Biomedical Materials for Tissue and Organ Regeneration, Collaborative Innovation Center of Regenerative Medicine and Medical Bioresource Development and Application Co-Constructed By the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, 530021, PR China.
Abstract:
The clinical management of osteosarcoma faces critical challenges, including postoperative recurrence and metastasis of residual tumor cells, chemotherapy resistance, and impaired self-repair capacity due to extensive bone defects following tumor resection. Herein, we develop a novel functionalized 3D-printed scaffold with NIR-II responsiveness (BGS/I-LDH@MgO2), designed to simultaneously address the dual needs of inhibiting osteosarcoma recurrence and promoting bone regeneration. This scaffold consists of 3D-printed bioactive glass scaffold (BGS) and MgO2-modified ZnAl-layered double hydroxides (ZnAl-LDHs) intercalated with 5-iodo-isophthalic acid (I-IPA). Under NIR-II irradiation, the scaffold effectively triggers a photodynamic therapy (PDT) effect to eliminate osteosarcoma cells. Notably, the incorporation of MgO2 enables oxygen release within the tumor microenvironment, alleviating hypoxia and enhancing PDT efficacy for superior antitumor performance. Furthermore, the degradation of ZnAl-LDHs and MgO2 releases Mg2+ and Zn2+ ions and generates a mildly alkaline microenvironment, which collectively facilitate the osteogenic differentiation of bone marrow mesenchymal stem cells and accelerate the process of bone healing. This functionalized 3D-printed scaffold demonstrates excellent anti-tumor and osteogenic properties, showing great promise for the treatment of osteosarcoma-associated bone defects.
Insights
This study presents a novel 3D-printed scaffold that uses near-infrared II (NIR-II) light to treat osteosarcoma recurrence and promote bone healing. The scaffold combines photodynamic therapy with ion release for enhanced anti-tumor and bone regeneration effects.
Area of Science:
- Biomaterials Science
- Oncology
- Regenerative Medicine
Background:
- Osteosarcoma treatment faces challenges like recurrence, metastasis, and poor bone repair after surgery.
- Existing therapies often struggle with chemotherapy resistance and hypoxia in the tumor microenvironment.
Purpose of the Study:
- To develop a functionalized 3D-printed scaffold for simultaneous osteosarcoma treatment and bone defect regeneration.
- To create a scaffold responsive to NIR-II light for targeted photodynamic therapy (PDT) and enhanced bone healing.
Main Methods:
- Fabrication of a 3D-printed bioactive glass scaffold (BGS) incorporating MgO2-modified layered double hydroxides (LDHs) intercalated with 5-iodo-isophthalic acid (I-IPA).
- Evaluation of the scaffold's NIR-II responsive photodynamic therapy (PDT) efficacy against osteosarcoma cells.
- Assessment of oxygen release from MgO2 to combat tumor hypoxia and enhance PDT.
- Analysis of ion release (Mg2+, Zn2+) and microenvironment changes to evaluate bone regeneration potential.
Main Results:
- The BGS/I-LDH@MgO2 scaffold demonstrated effective elimination of osteosarcoma cells via NIR-II triggered PDT.
- MgO2 incorporation enhanced PDT by releasing oxygen and alleviating tumor hypoxia.
- Scaffold degradation released Mg2+ and Zn2+ ions, promoting osteogenic differentiation and accelerating bone healing.
- The scaffold exhibited significant anti-tumor and osteogenic properties.
Conclusions:
- The developed functionalized 3D-printed scaffold shows significant promise for treating osteosarcoma recurrence and associated bone defects.
- This dual-action scaffold offers a novel therapeutic strategy by combining targeted cancer therapy with enhanced bone regeneration.
